The 3rd International Online Conference on Cells
The 3rd International Online Conference on Cells
Charming Micro-Insights into Health and Diseases
Part of the International Online Conference on Cells series
Event's Timezone: Central European Time
19th January 2025
14th February 2025
18th February 2025
11th February 2025
20th March 2025
Cellular signalling, Cancer treatment, Senescence Aging, Neurodegeneration, Development, Cellular Immunology
Abstract Submission Deadline has been extended!
New submission deadline: 19 January 2025
Join us today to register and submit your abstract, and be part of cutting-edge discussions and networking opportunities!
Welcome from the Chair
On behalf of Cells (ISSN: 2673-9976; IF: 5.1) I welcome you to our 2025 Virtual Conference. As with our previous 2 conferences of this series, we want to provide a highly interactive platforum for researchers all over the world to discuss major achievements as well as challenges in cell biology. Our goal is to cover a wide range of topics and to get feedback from seasoned researchers and from young investigators. Cells is a very dynamic journal with its eyes and ears always open to discoveries and novel emerging directions in cell biology. The goal of our 2025 Virtual Conference is to facilitate interaction between participants and to further advance the highly collaborative spirit of cell biology science. By covering such topics as cellular pathology of cancers, neural cell biology, cellular antivirus immune responses, cell therapies, cellular signaling, cell research in animal models, cellular metabolism, protein quality control, proteasomal degradation and autophagy, Cells remains at the forefront of scientific discourse. Over time, Cells has gained a reputation as a solid scientific journal, due to its unbiased peer-review process and great attention to every submitted paper.
We are privileged to host the 3rd Online Conference and are looking forward to oral presentations which shed light on complex mechanisms underlying cellular physiology and suggest novel treatment strategies for a wide spectrum of life-threatening pathologies.
Let us exchange provocative ideas, meet collaborators and enjoy the world of science with its incredible surprises and discoveries.
Download the conference flyer and share it with your colleagues!
Event Chair
Prof. Dr. Alexander E. Kalyuzyhny received his B.S. and M.S. from the Department of Biochemistry and Biophysics at the Saratov State University (Russia) in 1981. He investigated the mechanisms underlying the pre-implantation development of mouse embryos. Between 1983 and 1988, he investigated the effects of narcotic substances on early morphogenesis, receiving his Ph.D. in 1988. In 1992, Dr. Kalyuzhny moved to the USA to join the Department of Pharmacology at the University of Minnesota Medical School. Later, he joined the Department of Neuroscience at the university where he was then affiliated as a Research Assistant Professor. His academic research interests are focused on the mechanisms underlying the functions of opioid receptors. Since 1998, Dr. Kalyuzhny has been involved in both teaching and editorial work.
Session Chairs
Prof. Dr. Srinivasan Madhusudan
Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK
Srinivasan Madhusudan is the Professor of Medical Oncology and Director of Naaz-Coker Ovarian cancer Research Centre at the Biodiscovery Institute, School of Medicine, University of Nottingham. His clinical expertise is in the management of Ovarian and Breast Cancers. His pre-clinical laboratory is focussed on translational DNA damage signalling and repair in cancers.
Prof. Dr. Natália Ana Pereira Da Cruz Martins
Advanced Polytechnic and University Cooperative (CESPU), Faculty of Medicine, University of Porto (FMUP), Portugal
-
Prof. Dr. George Smith
1. Shriners Hospitals Pediatric Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, USA 2. Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, USA
After graduating with a BS in Chemistry Dr. Smith moved to Case Western Reserve University and completed his graduate studies in the Department of Developmental Genetic and Neurosciences under the mentorship of Dr. J Silver. During this time, he worked on the changing role of astrocytes from growth promoting (immature) to scar forming (mature). He also coauthored 3 patents, leading to the formation of the Biotech company, Gliatech, Inc. with Dr. Silver. After graduation, Dr. Smith moved to Baylor College of Medicine for postdoctoral studies, where he examined the roles of neurotrophins in regeneration. In 1991, he started his first laboratory at UT Southwestern Medical Center as an Assistant Professor studying the role of neurotrophins in regeneration of sensory afferents into the spinal cord. He also became interested in and joined the BME program developing filamentous nerve growth conduits. We were the first groups to examine the use of bioresorbable filaments to guide axons across the conduit. This research led to authorship on numerous manuscripts and 3 patents. In 2001, Dr. Smith was recruited as an Associate Professor to the Spinal cord and Brain Injury Research Center (SCoBIRC) at the University of Kentucky continuing his work on neurotrophins in spinal cord injury and Parkinson’s disease. Where he furthered his work constructing and producing various recombinant virus systems to examine regeneration and targeting of transplanted neurons. In 2011, Dr. Smith moved to Philadelphia to study pediatric spinal cord injury. There he changed his research direction from neurotrophins to motor control. He is presently Professor and Vice Chair of the Department of Neural Sciences and Director of the Center for Neural Development and Repair. The primary goal of his laboratory is to enhance axon regeneration and circuit reformation of the spinal cord after injury or in neurodegenerative disorders, with the long-term goal of developing and transferring treatments to human patients.
Prof. Ratna B. Ray
Department of Pathology, Saint Louis University, Saint Louis, USA
Dr. Ratna Ray did her PhD from the University of Calcutta, India. She has her post-doc training at the University of Alabama at Birmingham. She joined Saint Louis University as an Assistant Professor and rose to the rank of Professor in 2005. Dr. Ray' lab is working to understand the mechanisms of hepatitis C virus persistence and end stage liver disease progression in humans. Her research group made a significant contribution in understanding the crosstalk between HCV and host cell factors in disease progression. Recently, her laboratory-initiated work on non-coding RNAs regulation, and currently plans to understand the relationship between ncRNAs and liver disease progression. In addition, her laboratory is engaged in cancer biology work. She is an active member in the cancer and virology research communities, served as permanent and frequent ad-hoc member of NIH study sections, served as a reviewer, editorial board member, and academic editors for scientific journals.
Prof. Dr. Maciej Kurpisz
Institute of Human Genetics, Polish Academy of Sciences, Department of Reproductive Biology and Stem Cells, Poznan, Poland
Professor Maciej Kurpisz is an independent team leader, Head of Department of Reproductive Biology and Stem Cells, Institute of Human Genetics Pol. Acad.Sci., Poznan, Poland. He graduated medicine (1980), Poznan Medical University where he has accomplished first doctorate (1983) and then post doc trainings in London Hospital Medical College, UK (183-1985) as well as in Oregon Primate Research Center and Jones Institute for Reproductive Medicine, Norfolk, (USA 1986-1989). He is also a honoris causa doctorate recipient of Lviv National Medical University. His major scientific contributions include human genetics, imunology andrology and stem cell application. Numerous collaborations with the United States, United Kingdom, Germany etc. enabled him to co-discover novel genes: TEX-11 -responsible for meiosis resumption, CGNA – participating in male infertility and cancerogenesis, he also performed in silico assay for human genes and corresponding mouse knock-outs allowing him to publish in top journals. For his outstanding achievements in science awarded by President of Poland (2024) with Officer’s Cross of Polonia Restituta.
Dr. Mohammad Asim
Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, UK
Dr. Mohammad Asim is a Cancer Molecular Biologist who studies molecular mechanisms that drive prostate cancer progression in order to find novel and more effective treatments. His research has primarily focussed on understanding the role of the androgen receptor signalling in prostate cancer and how it is activated in cancer leading to drug resistance. Mohammad graduated with a PhD from Justus Liebig University for his work uncovering the role of signal transduction pathways and transcriptional corepressors in regulating androgen receptor signalling in prostate cancer. Following a postdoc in Cancer therapeutics at the University of Wisconsin, where he discovered novel anti-androgens, he took up a Senior Scientist position at the Cancer Research UK Cambridge Institute at the University of Cambridge. Here, Mohammad's ground-breaking work identified the first-ever mammalian kinase that can act as a chaperone for the androgen receptor and is a drug target. At Surrey, his work uncovered a novel synthetic lethal relationship between the androgen receptor and Poly (ADP-Ribose) Polymerase pathway which is being clinically exploited to treat castration-resistant prostate cancer (CRPC). His lab identified PDZ binding Kinase as a mediator of androgen receptor function in CRPC thus revealing the molecular mechanism underlying the failure of hormone therapy for prostate cancer. This work contributed to understanding pathways that can cause the failure of hormone/radiation therapy and can thus be exploited in developing combination approaches for effective cancer treatment. For his discoveries on a novel dual-activity anti-androgenic drug currently in development, Dr Asim was awarded a Young Investigator Award from the Prostate Cancer Foundation. In addition to his role at Surrey, Dr Asim concurrently holds a visiting scientist post at the University of Cambridge.
Prof. Dr. Santhi Gorantla
College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
Dr. Susanta K. Behura
Division of Animal Sciences, University of Missouri, Columbia, MO, USA
Prof. Dr. Roger Schneiter
Department of Biology, University of Fribourg, Fribourg, Switzerland
Roger Schneiter is a Professor of Biochemistry at the Department of Biology of the University of Fribourg, Switzerland. His laboratory is focused on the characterization of molecular mechanisms of lipid droplet biogenesis in the unicellular model eukaryote baker's yeast and the characterization of CAP superfamily proteins in plants and fungal phytopathogens.
Prof. Dr. Fulvio Mario Reggiori
Department of Biomedicine, Aarhus University, Aarhus, Denmark
Fulvio Reggiori studied Biochemistry at University of Fribourg, Switzerland, and in 1997, he obtained his PhD in Biochemistry from the same Institution. Here, in the laboratory of Prof. Andreas Conzelmann, he has worked on the remodelling of the lipid moiety of GPI-anchored proteins and on sphingolipid biosynthesis in yeast Saccharomyces cerevisiae. After staying one additional year in the same laboratory as a postodoctoral fellow, he moved to the MRC Laboratory of Molecular Biology in Cambridge, United Kingdom, in 1998. There, in the laboratory of Dr. Hugh Pelham, he has investigated the signals targeting integral membrane proteins into the internal vesicles of multivesicular bodies. In 2001, he joined the laboratory of Prof. Daniel Klionsky at the Life Sciences Institute of the University of Michigan in Ann Arbor (USA). There, he started working on different aspects of the molecular mechanism of autophagy in yeast. In 2005, Fulvio Reggiori was appointed as a tenured Assistant Professor at the Department of Cell Biology of the University Medical Center Utrecht, The Netherlands, where he started is independent research career working on the molecular mechanism of autophagy. The laboratory interests also extended to pathogens that subvert autophagy to invade host cells. In 2011, he became an Associate professor at the same Institution. 2015-2022, Fulvio Reggiori became Professor at the Department of Cell Biology of the University Medical Center Groningen, The Netherlands, where he continued his investigation on the molecular mechanism of autophagy in yeast and on the interaction between pathogens and the ATG proteins. In May 2022 the Reggiori group moved to the Aarhus University in Denmark, where he is still studying the same topics but also the role of autophagy in preventing neurodegeneration.
Professor Paul Gissen
UCL Great Ormond Street Institute of Child Health, London, UK, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
-
Event Committees
Arthur A. Dugoni School of Dentistry, University of the Pacific, USA
Division Pharmacology, Karl Landsteiner University of Health Sciences, Austria
Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Institute of Biochemistry, University of Palermo, Italy
Department of Otorhinolaryngology, Medical University Innsbruck, Innsbruck, Austria
The Society for the Investigation of Early Pregnancy (SIEP), New York, USA
Radiation Physiology Laboratory, Singapore Nuclear Research and Safety Initiative, National University of Singapore, Singapore
Department of Molecular Neurobiology, Institute for Developmental Research, Aichi Developmental Disability Center, Japan
Medical education in Bern and Geneva, MD 1978. PhD 1984 and FMH in pathology 1988 in Basel. Positions held: 1974 Immunology University of Bern, 1979 Pharmacology, Sandoz Pharma Basel, 1991 University of Zurich, Pharmacology-Toxicology, Immunology University Cape Town, RSA. Since 2001 Director of research, CNRS Immunology, Orleans, France with active research, and advisor of several pharmaceutical companies. Founder of IBR Inc, Artimmune SAS and Phenotec AG. Research: Mechanisms of inflammation, especially respiratory inflammation, fibrosis, emphysema and COPD, but also in skin, hepatic, intestinal, renal and CNS inflammation: Innate immune danger sensing and cGAS/STING, ROS and Inflammasome activation in models of human inflammatory diseases and tumor development, role of microbiome and metabolome. Role of TNF and IL-1 members, in cell death and IL-33 and T2 / T17 polarization and differentiation. APB drug candidate Stable butyrate to treat chronic lung inflammatory disease.
Department of Life Science, Health and Health Professions, Link Campus University, Roma, Italy
i3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Cellular Neurobiology Laboratory, Neurobiology Division, Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, USA,
Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, Memphis, TN, USA
Laboratory of Physiological Hygiene and Exercise Science, School of Kinesiology, University of Minnesota, Minneapolis, MN, USA
Department of Biochemistry & Molecular Biology, Tulane University School of Medicine, LA, USA,
Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA,
Tulane Aging Center, Tulane University School of Medicine, New Orleans, LA, USA
Department of Neurology, St. Joseph Hospital, Gartenstr. 1, Berlin, Germany
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Department of Molecular Physiology and Biophysics, Vanderbilt School of Medicine Basic Sciences,
Vanderbilt University, Nashville, TN, USA
UCL Great Ormond Street Institute of Child Health, London, UK,
Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
Institut Jean-Lamour, Université de Lorraine, France
Department of Ecological and Biological Sciences, University of Tuscia, Italy
Whitaker Cardiovascular Institute, Department of Medicine, Vascular Biology Section, Chobanian & Avedisian School of Medicine,
Boston, MA, USA
Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Italy
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale, Italy
Department of Nuclear Medicine, Philipps University Marburg, Marburg, Germany
Department of Cell Death and Proliferation, Institut d’Investigacions Biomèdiques de Barcelona (IIBB-CSIC), Institut
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Department of Biomedical Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Stem Cell and Tissue Engineering Laboratory, Department of Orthopaedics, West Virginia University, Morgantown, USA
Institute of Post Graduate Medical Education and Research,Kolkata, India
Valrose Biology Institute, Côte d'Azur University, Nice, France
Keynote Speakers
The Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Faculty of Medical and Health Sciences, School of Medicine, The Adams Super Center for Brain Studies and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
Protein Folding and Quality Control, Institute for Research in Biomedicine (IRB), CH-6500 Bellinzona, Switzerland
ERAD and ERLAD: The proteasomal and lysosomal clearance of misfolded proteins from the endoplasmic reticulum
The research group of Maurizio Molinari at the IRB in Bellinzona aims at the characterization of molecular mechanisms that control size, activity and homeostasis of the ER, the major biosynthetic organelle of nucleated cells. The group identified SEC62 as the ER-phagy receptor activated during recovery from ER stress to remove excess portions of the ER and of the outer nuclear membrane to re-establish the physiologic ER and nuclear envelope ultrastructure and activity. The group also reported the first example of ER-phagy receptor (FAM134B)-mediated clearance of ER portions containing terminally misfolded polypeptides, named these catabolic processes ER-to-Lysosome-Associated Degradation (ERLAD), and showed that ERLAD acts in concert with ER-associated degradation (ERAD), which relies on the intervention on the ubiquitin/proteasome system, to efficiently remove from cells toxic and aberrant gene products.
Department of Immunology and Microbiology, South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA
Clinical significance of targeting ribosome biogenesis for cancer therapy
Dr. Hafeez is an Assistant Professor in the department of Medicine and Oncology at the University of Texas Rio Grande Valley School of Medicine and has a broad background in cancer biology, molecular therapeutics, and molecular biology with specific expertise in generating various pre-clinical mouse models of solid tumors. He has also generated various mouse models (orthotopic, xenograft, conditional Pten-knockout and transgenic) of prostate cancer. Currently, his lab research is dedicated to understanding the molecular mechanisms of ribosome biogenesis dysregulation in solid tumors and how targeting ribosome biogenesis by RNA polymerase inhibitor can suppress the growth of advanced pancreatic cancer. Dr. Hafeez serves both PI and Co-I on multiple NIH-funded grants and has published more than 60 high-impact cancer research articles in peer-reviewed journals.
Invited Speakers
Department of Biomedical, Dental Sciences and Morphofunctional Images, University of Messina, Messina, Italy
I am Luigi Donato, born in Catania on July 9, 1986. I graduated in Biology from the University of Messina, Italy, and completed my PhD in “Applied Biology and Experimental Medicine” at the age of 32 from the same university. My career is anchored at the Laboratories of Molecular Genetics, Department of Biomedical and Dental Sciences and Morphofunctional Imaging (BIOMORF) at the University of Messina, where I have been awarded an Assistant Professor position through a competitive selection process. Additionally, I serve as a researcher at the Euro-Mediterranean Institute of Science and Technology (IEMEST) in Palermo, Italy, where I have taught in the Bioinformatics and Science Applied Statistics master program. With over 100 published papers in reputed journals and participation in more than 60 national and international congresses, my work has significantly contributed to the field of molecular genetics and biomedical research, with a special focus on retinal degenerative diseases. I am a member of the Executive Committee of the Low Vision Academy (LVA) and a recognized full member of Sigma Xi, The Scientific Research Honor Society. My editorial experience includes serving on the boards of journals such as CellPress Heliyon, BMC Bioinformatics, and Cell Cycle, as well as acting as a Guest Editor for Antioxidants and Life. In 2020, I was the editor and an author of the book “Advances in Bioinformatics Biostatistics and Omic Sciences”. My main research fields focus on rare diseases, particularly retinal dystrophies and omics approaches. Recently, I have expanded my research to include studies on mitochondrial DNA using NGS approaches.
Laboratory of Virology, Regional Centre for Biotechnology, Faridabad, India
Dr. Arup Banerjee, obtained his PhD from Jadavpur University, Kolkata, India. He was a postdoctoral fellow at Internal Medicine, Centre for Vaccine Development, Saint Louis, MO, USA., where he worked on understanding the molecular basis for Hepatitis C virus-induced insulin resistance. In 2011, he joined the DBT-Translational Health Science and Technology Institute (THSTI), India, as a Research Scientist. In August 2018, he joined the Regional Centre for Biotechnology (RCB) in Faridabad, India, as an Associate Professor. The core area of his research revolves around understanding the host's immune response against invading viral pathogens, especially Dengue and Japanese Encephalitis virus (JEV). His research group at the RCB, Faridabad, is currently involved in deciphering the impact of viral infection on neutrophil phenotypes and function and how those phenotypically altered neutrophils are involved in disease outcomes. Dr. Banerjee's work is notable for using primary human cells and animal models to demonstrate immune-related mechanisms and illuminate potential avenues for therapeutic interventions. His team also developed small animal models to facilitate drug screening studies and immune responses against Japanese Encephalitis viruses. In addition, his laboratory is engaged in extracellular vesicle research to understand disease biology and identify novel interventions for viral infections. He is an active member of virology and extracellular research communities and has served as a reviewer, editorial board member, and guest editor for scientific journals.
Molecular Cell Biology Section, Department of Biomedical Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Since the start of his research career Mario Mauthe was focusing on understanding the cellular degradation and recycling pathway of autophagy. First, he studied in great detail the involvement of the WIPI protein family members in autophagy, looking in particular at their role in signaling, bacterial defense and metabolism. He conducted this research in the laboratory of Prof. Tassula Proikas-Cezanne, the main scientist that identified and characterized the function of WIPI proteins in autophagy. Mario Mauthe obtained his PhD in molecular biology in the laboratory of Prof. Tassula Proikas-Cezanne in Tuebingen (Germany) studying in great detail the involvement of the WIPI protein family members in autophagy. For his Postdoc research, he joined the laboratory of Prof. Fulvio Reggiori in the Netherlands and studied the functions of autophagy-related (ATG) proteins outside the context of autophagy. As an assistant professor at the UMCG (Groningen, the Netherlands), his research focusses on the relevance of autophagy in neurodegenerative diseases. He studies at the molecular level how autophagy, and more specifically a selective type of autophagy called aggrephagy, contributes to the clearance of these aggregates. To do so, he is employing a novel cellular system that was recently developed in his former laboratory. Furthermore, and based on his expertise on WIPI proteins, he is investigating WDR45/WIPI4 and its contribution to BPAN pathophysiology.
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, 27710 Durham, USA
Dr. Rachid Safi is an Assistant Research Professor in the Department of Pharmacology and Cancer Biology at Duke University School of Medicine. His research focuses on elucidating the molecular mechanisms that drive prostate cancer resistance to endocrine therapies, with the goal of identifying novel, targetable nodes for more effective therapeutics. Dr. Safi obtained his PhD from the École Normale Supérieure de Lyon in France before joining the laboratory of Donald McDonnell at Duke University for his postdoctoral training. At Duke University School of Medicine, he applied mechanism-based approaches to develop cancer therapeutics targeting nuclear receptor signaling. His significant scientific contributions include selective aromatase inhibition in breast cancer, expanding hematopoietic stem cells, exploiting oxidative stress in cancer cells, targeting cancer cell metabolism to overcome resistance, and identifying novel treatments for metastatic breast and prostate cancers. Dr. Safi has been awarded multiple research grants and plays a role as an educator, mentoring students, and young researchers, and serves as an ad hoc reviewer for scientific journals.
Department of Life Science, Health and Health Professions, Link Campus University, Roma, Italy
Link Campus University, Roma, Italy
Division of Infectious Diseases, Allergy and Immunology, St. Louis University School of Medicine, 1100 S. Grand Blvd, St. Louis, MO 63104, USA
My independent research career focuses on infectious diseases, both basic virology/viral interactions and human immune responses to infectious pathogens and vaccines. I have been the PI on 2 VA Merit Review awards, 2 VA RCD awards, 3 NIH awards, 3 Industry awards, and 12 vaccine/treatment clinical trials (7 sponsored by the NIH). Research awards in the past 3 years include: 1) PI on a VA Merit Review award examining durable immune responses after dengue vaccination vs. infection, 2) on an NIH contract evaluating T cell responses in flavi-naïve and experienced recipients of a Zika vaccine, 3) collaboration on an R01 focused on understanding the antibody response to Zika in flavi-naïve and experienced people, 4) PI on 5 vaccine/treatment trials, one funded by NIH. My research has focused on adaptive and innate human immunity after vaccinations and during viral infections, including immunity during and after dengue and Zika vaccination, dengue infection, COVID infection and vaccination, HPgV/HIV interactions in vivo and in vitro, and seronegative chronic HCV infection (recent collaborative publications listed below). We have characterized T and B cell immunity in previously seronaive people in a flavivirus non-endemic area 10 years after vaccination, durable immunity after dengue infection, and cellular immunity after Zika vaccination in flavi-naives. I have previously received VA Merit Review funding for dengue research and produced 2 accepted manuscripts with a 3rd pending (manuscript completion delayed due to COVID). I am an experienced flavivirus researcher, vaccinologist, and clinical trialist, and my laboratory and collaborators have the expertise needed for this project, which is vital to advancing our understanding of type, specificity, and durability of dengue immunity after vaccination and infection.
Dr. Hemant Mishra is a driven and results-oriented organizational leader with over a decade of experience in the biotech industry and academia. Specializing in target discovery and preclinical development of biologics, Dr. Mishra has a proven track record in guiding cross-functional teams and fostering collaborations in immuno-oncology. Expertise includes cell therapies such as stem cells, NK cells, and T cells, as well as antibody development and targets like Bike, Trike, and myeloid cells. Currently, he serves as the Managing Director of Golden Gate MLabs, a stealth startup company which is working on novel cutting edge products for immunotherapeutics. Previous to that, Dr. Mishra served as the Director and Head of Allogeneic Cell Therapy and Stem Cell Gene Therapy at Cellinfinitybio, where they led the development of off-the-shelf allogeneic therapies targeting solid tumors using advanced techniques like CRISPR-mediated directed evolution. In addition to his leadership roles, Dr. Mishra has made significant contributions to the academic field, conducting groundbreaking research at the University of Minnesota on engineered NK and T cells and host-pathogen interactions, with numerous publications to his name. This combination of scientific innovation and strategic leadership makes Dr. Mishra a versatile and highly appreciated figure in the field of cell and gene therapy.
Department of Animal Science, University of Tennessee Institute of Agriculture, Knoxville, TN
Dr. Daniel Mathew received his PhD with a focus in Reproductive Physiology from the Division of Animal Sciences at the University of Missouri, Columbia, USA. During his program he investigated the role of placental IL-1 cytokines during establishment of pregnancy in swine. Dr. Mathew then completed a Post-Doctoral Fellowship at the University College Dublin, Ireland, where he used endometrial cell and tissue culture models to investigate paracrine crosstalk associated with in vitro produced bovine embryos. He is now an Assistant Professor in the Department of Animal Science at the University of Tennessee, Knoxville, USA. There, Dr. Mathew teaches Animal Anatomy and Physiology and investigates interactions between the in vitro produced bovine embryo and endometrium as it relates to early embryonic mortality.
Sessions
SESSION B. Neural Cell Biology
SESSION C. Cellular Antivirus Immune Responses
SESSION D. Cell Therapies
SESSION E. Cellular Signaling
SESSION F. Cell Research in Animal Models
SESSION G. Cellular Metabolism
SESSION H. Protein Quality Control, Proteasomal Degradation and Autophagy
Registration
When registering as an "Academic", please register with your academic email address, as this will accelerate the registration process. If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for understanding.
Participation to the conference is considered final only once the registration fees have been paid. The number of participants is limited: once the number of paid registrations reaches the maximum number of participants, unpaid registrations will be cancelled.
Please note that, in order to finalize the scientific program in due time, at least one registration by any of the authors, denoted as the “Covering Author”, is required to cover the presentation and publication of any accepted abstract. The “Covering Author” registration deadline is 11 February 2025. Your abstract will be withdrawn if your registration is not completed by this date.
Finally, only registered authors will be able to apply for the Conference Awards.
Group Discounts:
-
Group of 3, 5% off;
-
Group of 5 or more, 10% off;
-
Group of 10 or more, 15% off
|
Early Bird Until 18th February 2025 |
Regular Until 20th March 2025 |
Supported documents | |
|---|---|---|---|
| Author, Reviewers, Topical Advisory Panel Members, Review Board Members, Guest Editors | 30.00 CHF | 50.00 CHF | |
| Student | 30.00 CHF | 50.00 CHF |
Please upload the front and back of your valid Student lD card. |
| Academic | 40.00 CHF | 60.00 CHF | |
| Non-Academic | 100.00 CHF | 150.00 CHF | |
| Chairs, Invited Speakers, Committee Members of the Conference, MDPI Guests, Editorial Board Members | Free | Free |
Cancellation policy
| > 2 weeks before the conference | Full refund |
| < 2 weeks before the conference | No refund |
Disclaimer
We will endeavour to present the program advertised. However, MDPI and its partners reserve the right to alter or cancel, without prior notice, arrangements, timetables, plans, or other items relating directly or indirectly to The 3rd International Online Conference on Cells: Charming Micro-Insights into Health and Diseases. MDPI and its partners are not liable for any loss or inconvenience caused as a result of such cancellation.
Beware of Unauthorized Registration
Note that Sciforum is the only official registration platform to register to CELLS 2025. Beware that entering into financial agreements with non-endorsed companies can have costly consequences.
Insurance
The organizers do not accept liability for personal accident, loss, or damage to private property incurred as a result of participation in the event.
Payment methods
Wire transfer, Credit card
Currencies accepted by this event
Swiss francs (CHF) , Euros (EUR) , US dollars (USD) and Singapore dollars (SGD)
Instructions for Authors
The 3rd International Online Conference on Cells: Charming Micro-Insights into Health and Diseases will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
1. Deadline for abstract submission: 15 December 2024 19 January 2025.
2. Announcement of oral and poster abstract results: 15 January 2025 14 February 2025. You will be notified of the acceptance of an oral/poster presentation in a separate email.
Abstract submissions should be completed online by registering with www.sciforum.net and using the "New Submission" function once logged into the system. No physical template is necessary.
1. The structure abstract should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All accepted abstracts will be published in the conference report of Cells2025 in MDPI’s Biology and Life Sciences Forum journal (ISSN: 2673-9976) after quality check. If you wish to publish a research article in the journal, please refer to the “Publication Opportunities” Section.
3. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
4. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
5. The abstracts submitted to this conference must be original and novel, without prior publication in any journals or it will not be accepted to this conference.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
a. Your submission should include the title, authors, contact details, and main research findings, as well as tables, figures, and graphs where necessary.
b. File format: PDF (.pdf).
c. Size in cm: 60 width x 80 height–portrait orientation.
d. Font size: ≥20.
e. Maximum size: 250 M
You can use our free template to create your poster. The poster template can be downloaded here.
Authors who wish to present a poster are invited to send it to the conference email at cells2025@mdpi.com. All posters will be permanently exhibited online in the Poster Gallery.
It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunities
1. Cells Journal Publication
Participants in this conference are cordially invited to contribute a full manuscript to the conference's Special Issue "Charming Micro-Insights into Health and Diseases", published in Cells ( ISSN: 2073-4409, Impact Factor 5.1), with a 10% discount on the publication fee. Please note if you have IOAP/association discounts, conference discounts will be combined with IOAP/association discounts. Conference discounts cannot be combined with reviewer vouchers. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
Manuscripts for the proceedings issue must be formatted as follows:
-
Title.
-
Full author names.
-
Affiliations (including full postal address) and authors' e-mail addresses.
-
Abstract.
-
Keywords.
-
Introduction.
-
Methods.
-
Results and Discussion.
-
Conclusions.
-
Acknowledgements.
-
References.
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide 3 awards including Best Oral Presentation Award and Best Poster Award.
The Awards
Number of Awards Available: 3
The Best Oral Presentation Award is given to the submission judged to make the most significant oral contribution to the conference.
The Best Poster Award is given to the submission judged to make the most significant and interesting poster for the conference.
There will be three winners selected for these awards. The winner will receive a certificate and 200 CHF each.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
Conference Secretariat
Ms. Dorothy Cai
Ms. Katrina Zhang
